Log In
BCIQ
Print this Print this
 

Striverdi Respimat, Olodaterol (BI 1744)

  Manage Alerts
Collapse Summary General Information
Company Boehringer Ingelheim GmbH
DescriptionLong-acting beta 2 agonist (LABA)
Molecular Target Adrenergic receptor beta 2 (ADRB2)
Mechanism of ActionAdrenergic receptor beta 2 (ADRB2) agonist
Therapeutic Modality 
Latest Stage of DevelopmentApproved
Standard IndicationChronic obstructive pulmonary disease (COPD)
Indication DetailsTreat chronic obstructive pulmonary disease (COPD)
Regulatory Designation U.S. - Undisclosed Review (Treat chronic obstructive pulmonary disease (COPD));
EU - Standard Review (Treat chronic obstructive pulmonary disease (COPD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

08/30/2016

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today